The treatment protocols for metastatic NSCLC patients, without mutations in epidermal growth factor receptor (EGFR) and BRAF genes or without rearrangements in anaplastic lymphoma kinase (ALK) and ROS1 genes, were based on chemotherapy, namely platinum doublets in first line setting and docetaxel or pemetrexed in second line treatment. The gene discussed is ALK; the disease is non-small cell lung carcinoma.